UCB's Neupro available again in the EU
This article was originally published in Scrip
UCB is making available again its transdermal patch, Neupro (rotigotine), in the EU, following approval by the European Commission of last month's positive opinion from the CHMP (scripnews.com, June 1st, 2009). It is indicated for the treatment of Parkinson's disease and a new indication, restless legs syndrome.
You may also be interested in...
Pipeline Watch is a weekly snapshot of selected late-stage clinical trial events and approvals announced by pharmaceutical and biotech companies at medical and industry conferences, in financial and company presentations, and in company releases and statements.
Europe’s strengths in the biotech space include world-class science, but the continent needs to build on its strengths in order to deliver on the promise of a coming “golden age” of biotech, says a recent report.
Top-line results from the Phase III TULIP study show that Byondis’s next-generation antibody-drug conjugate, trastuzumab duocarmazine (SYD985) is superior to physicians' choice of therapy for delaying disease progression in patients with advanced HER2-positive breast cancer.